browsing investors dashboard contactyoutubelinkedintwitter englishespa ol pharmamar s.a. about pharmamar about pharmamar senior management management team oncology unit board of directors other business pharmamar in the world awards & recognition corporate responsibility our history patients therapeutic indications collaboration with patient associations yondelis science & innovation r & d and innovation oncology pipeline cofinanced projects collaboration with scientific associations publications action mechanisms shareholders and investors financial information annual reports quarterly reports financial statements zeltia average period of payment to suppliers official notices to the cnmv pharmamar zeltia share information share performance shares & stock capital dividends significant shareholding & company owned stock analysts fixed income issues presentations general shareholders meetings corporate governance corporate bylaws general shareholders meeting regulations shareholder agreements board of directors board regulations annual report on corporate governance annual director remuneration report board committees internal regulation governing conduct contact merger pharmamar zeltia newsroom press releases events calendar videos corporate brochure careers menu close back oncology business unit oncology pipeline pharmamar in the world other business biopharmaceutical sector chemical sector publications 6april 2015 trabectedin in patients with advanced soft tissue sarcoma a retrospective national analysis of the french sarcoma group 6april 2015 interruption versus continuation of trabectedin in patients with soft tissue sarcoma t dis a randomised phase 2 trial newsroom 10october 2016 pharmamar announces positive results from its phase ii study with lurbinectedin in brca 1 2 associated metastatic breast cancer at the esmo 2016 congress 5october 2016 pharmamar announces new clinical data on yondelis and lurbinectedin pm1183 to be presented at esmo 2016 investors financial informationofficial notices to the cnmvshare informationgeneral shareholders meetings pharmamar te proporciona toda la informaci n financiera posible sobre la marcha de pharmamar en bolsa memorias y cuentas anuales infornes trimestrales o periodos medios de pago de la corporaci n. anual reports quarterly reports financial statements average period of payment suppliers 30 10 2015 informaci n sobre resultados 30 10 2015 transformaciones fusiones escisiones y disoluciones . inscripci n en el registro mercantil de la escritura de fusi n por absorci n de zeltia s.a. por pharma mar s.a. 29 10 2015 transformaciones fusiones escisiones y disoluciones 24 10 2015 informaci n sobre resultados 23 10 2015 transformaciones fusiones escisiones y disoluciones share performance shares & stock capital dividends significant shareholding & company owned stock analysts the board of directors of pharma mar s.a. has resolved to call the annual general shareholders meeting to be held at instituto ferial de vigo ifevi on 23 june 2016 at 11 30 a.m. the venue for the aforementioned general meeting has been selected by the board of directors in accordance with the provisions of article 22 of the company s corporate bylaws . events this month calendar october 2016 m t w t f s s 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 mon 24 seom symposium . sociedad espa ola de oncolog a m dica october 24 8 00 am october 28 5 00 pm fri 28 aiom associazione italiana oncologia medica october 28 8 00 am october 30 5 00 pm sat 29 igcs october 29 8 00 am october 31 5 00 pm contact pharma mar s.a. avda . de los reyes 1 pol . ind. la mina 28770 colmenar viejo madrid spain cif a 78267176 918 466 000 pharmamar pharmamar.com 918 466 001 tweets by phrmmar . twitter newsletter suscribe to our newsletter and you will receive the latest news about pharmamar information about new avances data for investors and much more . subscribe pharma mar s.a.cif a 78267176 avda . de los reyes 1 pol . ind. la mina 28770 colmenar viejo madrid spain how to get 91 846 6000 91 846 6001 pharmamar pharmamar.com legal notice privacy policy cookies policy copyright 2016 pharmamar all rights reserved